For the roughly half of all spinal cord injury patients who endure chronic neuropathic pain, the search for relief has long meant choosing between imperfect medications and the well-documented dangers of opioids. A team of researchers at UC San Diego has now demonstrated, in animal trials, that a single injection of gene therapy can silence pain-signaling neurons at the precise site of injury for months at a time — without the side effects that have made existing treatments so difficult to live with. The path to human trials remains long and uncertain, but the study offers something the field
UPI News
· May 16, 2022
· health
· 2 min read
Medium
Sourcing: Characterized
Gene therapy shows promise for spinal cord injury pain in mouse studies
Approximately 50% of spinal cord injury patients experience chronic neuropathic pain, tingling, numbness, or muscle weakness that significantly impacts quality of life.
◉
Health & Medicine
8464 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% match
Related Coverage
The Guardian · Aug 26
ADHD and autism complaints triple as NHS waits stretch to years
Complaints about autism and ADHD services in England tripled in five years as NHS waits exceed a year for most patients,…
News-Medical · Aug 26 Sewage monitoring detects pertussis outbreaks 10 weeks earlier than clinical reportsWastewater surveillance in Osaka detected pertussis DNA 4-16 weeks before clinical case reports, offering a proactive ea…
The Hindu · Aug 26 India's H1N1 surge is seasonal, not a new strain, ICMR assuresIndia experiences seasonal H1N1 rise with 1,777 cases in Delhi and 4,212 in Karnataka; ICMR confirms it's the familiar p…
Medical Xpress · Aug 26 Stress gene hyperactivity linked to schizophrenia in University of Sydney studyUniversity of Sydney researchers discovered that a stress-regulating gene (FKBP5) remains abnormally active in schizophr…
Bias & Framing
No detailed analysis data available for this lens. Try re-running lenses from the admin panel.
Geopolitical Impact
🌎
This is a medical research article about gene therapy for spinal cord injury pain, not a geopolitical matter.
Escalation Risk
N/A
Confidence
HIGH
Economic Lens
📈
Gene therapy shows promise for treating spinal cord injury pain in mice, potentially reducing opioid dependence and creating new pharmaceutical/biotech market opportunities.
Market Signal
bullish
Confidence
MED
Biotechnology/Gene Therapy
Pharmaceutical Manufacturing
Healthcare Services
Medical Devices
Opioid Industry
Patients with spinal cord injuries and neuropathic pain could access non-opioid pain management alternatives, reducing addiction risks and medication side effects. However, high treatment costs and limited accessibility in early stages may restrict benefits to wealthy populations initially.
FDA may accelerate gene therapy approval pathways; healthcare regulators could shift reimbursement policies away from opioids toward gene therapies; potential reduction in opioid prescriptions could impact pharmaceutical revenue but improve public health outcomes; insurance coverage debates likely to emerge regarding cost-benefit of one-time gene therapy versus ongoing medication.